Увійти

Готові списки джерел за темами / Rabeprazole / Статті в журналах

Статті в журналах з теми "Rabeprazole"

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Rabeprazole.

Автор: Grafiati

Опубліковано: 4 червня 2021

Оновлено: 20 лютого 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Rabeprazole".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Cusimano, Joseph. "Rabeprazole." WikiJournal of Medicine 9, no. 1 (2022): 6. http://dx.doi.org/10.15347/wjm/2022.006.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Rabeprazole is a proton pump inhibitor that suppresses gastric acid production in the stomach. Available under different brand name products as well as in a variety of combination products, rabeprazole has several medical uses concerning the management of problems of pathological gastric acid. Rabeprazole's adverse effects tend to be mild but can be serious, including deficiencies in essential nutrients, rare incidences of liver damage, and immune-mediated reactions. As a class effect, rabeprazole can increase the risk for osteoporosis, serious infections (including Clostridium difficile infections), and kidney damage. Rabeprazole can theoretically contribute to numerous drug interactions, mediated both through its metabolic properties and its direct effect on acid in the stomach, though its potential for clinically meaningful drug interactions is low. Like other medications in the proton pump inhibitor class, rabeprazole's mechanism of action involves the irreversible inhibition of proton pumps in the stomach, which are responsible for gastric acid production. Rabeprazole has a number of chemical metabolites, though it is primarily degraded by non-enzymatic metabolism and excreted in the urine. Genetic differences in a person's drug-metabolizing enzymes may theoretically affect individual responses to rabeprazole therapy, though the clinical significance of this interaction is unlikely in comparison to other proton pump inhibitors. The purpose of this review is to provide an up-to-date monograph on rabeprazole.

2

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1394 (March 2012): 35. http://dx.doi.org/10.2165/00128415-201213940-00129.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1159 (July 2007): 25. http://dx.doi.org/10.2165/00128415-200711590-00075.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1373 (October 2011): 27. http://dx.doi.org/10.2165/00128415-201113730-00091.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Prakash, Amitabh, and Diana Faulds. "Rabeprazole." Drugs 55, no. 2 (1998): 261–67. http://dx.doi.org/10.2165/00003495-199855020-00009.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Bank, Simmy. "Rabeprazole." Drugs 55, no. 2 (1998): 268. http://dx.doi.org/10.2165/00003495-199855020-00010.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Takeguchi, Noriaki. "Rabeprazole." Drugs 55, no. 2 (1998): 268. http://dx.doi.org/10.2165/00003495-199855020-00011.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Langtry, Heather D., and Anthony Markham. "Rabeprazole." Drugs 58, no. 4 (1999): 725–42. http://dx.doi.org/10.2165/00003495-199958040-00014.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Carswell, Christopher I., and Karen L. Goa. "Rabeprazole." Drugs 61, no. 15 (2001): 2327–56. http://dx.doi.org/10.2165/00003495-200161150-00016.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Baldwin, Claudine M., and Susan J. Keam. "Rabeprazole." Drugs 69, no. 10 (July 2009): 1373–401. http://dx.doi.org/10.2165/00003495-200969100-00007.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1244 (March 2009): 38. http://dx.doi.org/10.2165/00128415-200912440-00113.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1256 (June 2009): 29. http://dx.doi.org/10.2165/00128415-200912560-00090.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1052 (May 2005): 17. http://dx.doi.org/10.2165/00128415-200510520-00054.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1330 (December 2010): 31. http://dx.doi.org/10.2165/00128415-201013300-00106.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1342 (March 2011): 28. http://dx.doi.org/10.2165/00128415-201113420-00100.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1422 (October 2012): 41–42. http://dx.doi.org/10.2165/00128415-201214220-00139.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1429 (November 2012): 35. http://dx.doi.org/10.2165/00128415-201214290-00132.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Duan, Zhenya, Yan Wang, Ling Zhang, Xing Cao, Lihua Fu, Zhenjiang Li, and Junmei Zhang. "An application of continuous flow microreactor in the synthesis and extraction of rabeprazole." International Journal of Chemical Reactor Engineering 19, no. 3 (March 1, 2021): 287–94. http://dx.doi.org/10.1515/ijcre-2020-0173.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Abstract The oxidation of rabeprazole sulfide is a key step in the synthesis of rabeprazole, a drug for the treatment of stomach acid-related disorders. The current rabeprazole production process adopts one pot batch process, which has low reaction efficiency and poor stability. A continuous process can greatly improve the production efficiency and solve the above problems. Therefore, the reaction parameters of rabeprazole in microreactor were explored through laboratory experiments to explore the possibility of continuous production of rabeprazole. Rabeprazole sodium was synthesized by using rabeprazole thioether as a raw material and sodium hypochlorite solution as the oxidant. Oxidation, quenching, acid-base regulation and extraction were completed continuously in the microreactor. Rabeprazole solution with a purity of 98.78% (±0.13%) can be obtained continuously in 56 s, whereas intermittent production lasted for at least 2 h. Thus, the microreactor can effectively improve the oxidation synthesis efficiency of rabeprazole, and provide reference for the realization of other reactions in the microreactor.

19

Jia, Rong-Jie, Xiao-Peng Wang, Zhen-Hua Zhang, Hai-Hong Cui, Rui Qin, Da-Yong Du, and Yang Liu. "Effect of Rabeprazole and Rebamipide in the Treatment of Upper Gastrointestinal Hemorrhage Associated with Dual Antiplatelet Therapy in Elderly Patients with Coronary Heart Disease." Clinical and Applied Thrombosis/Hemostasis 28 (January 2022): 107602962211307. http://dx.doi.org/10.1177/10760296221130746.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

To investigate the therapeutic effect of rabeprazole and rebamipide on patient age over 60 with dual antiplatelet therapy (DAPT)–related upper gastrointestinal hemorrhage following percutaneous coronary intervention (PCI). A total of 360 patients age over 60 undergoing PCI were recruited for antiplatelet therapy involving a combined treatment of aspirin (100 mg/d) and clopidogrel (75 mg/d). The enrolled patients were divided into 4 groups: the control group, the rabeprazole group, the rebamipide group, and the rabeprazole + rebamipide group. The incidence and severity of any upper gastrointestinal hemorrhage and the incidence of major adverse cardiac events (MACEs) were observed 6 months after the operation. The incidence of upper gastrointestinal hemorrhage in the 4 groups was 11.1%, 3.3%, 8.9%, and 1.1%, respectively, and the differences were statistically significant ( P < 0.05). On comparing the groups, the differences between the control group and the rabeprazole group, those between the control group and the rabeprazole + rebamipide group, and those between the rebamipide group and the rabeprazole + rebamipide group were found to be statistically significant ( P < 0.05). The severity of the upper gastrointestinal hemorrhage in the rabeprazole group and the rabeprazole + rebamipide group was significantly lower than that in the control group. The 4 groups exhibited no significant differences in the incidence of MACEs ( P > 0.05). For patients age over 60 receiving DAPT following PCI in our study population, treatment with rabeprazole or a combination of rabeprazole and rebamipide could reduce the risk of upper gastrointestinal hemorrhage, as well as reduce its severity.

20

&NA;. "Lansoprazole/rabeprazole." Reactions Weekly &NA;, no. 1097-1098 (April 2006): 18. http://dx.doi.org/10.2165/00128415-200610970-00057.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

&NA;. "Rabeprazole/terbinafine." Reactions Weekly &NA;, no. 864 (August 2001): 11. http://dx.doi.org/10.2165/00128415-200108640-00029.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

&NA;. "Aciphex (Rabeprazole)." Gastroenterology Nursing 23, no. 2 (March 2000): 88–89. http://dx.doi.org/10.1097/00001610-200003000-00011.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Lopina, O. D., B. K. Nurgalieva, and T. L. Lapina. "Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole." Russian Journal of Gastroenterology, Hepatology, Coloproctology 31, no. 4 (December 20, 2021): 55–63. http://dx.doi.org/10.22416/1382-4376-2021-31-4-55-63.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Aim. A comparative review of the rabeprazole properties vs. other PPIs, its efficacy and safety in treatment for aciddependent diseases.Key points. Rabeprazole provides a rapid proton pump blockade in parietal cells due to its high dissociation constant (pKa). A lower rabeprazole metabolic dependence on cytochrome P-450 enzyme system renders its antisecretory effect predictable and reduces the risk of interactions with other drugs metabolised through this system. A faster antisecretory effect and higher acid-suppressive activity of rabeprazole determine its better clinical efficacy in treatment for such acid-dependent diseases as gastroesophageal reflux disease and peptic ulcer. This makes rabeprazole (Pariet) a preferred drug in course and maintenance therapies for acid-dependent diseases, as well as in H. pylori eradication.Conclusion. The rabeprazole properties of high acid suppression potential, persistent antisecretory effect from first day of therapy, non-enzymatic metabolism and pleiotropic action determine its high efficacy in treatment for a wide range of acid-dependent diseases at a minimal risk of drug interaction.

24

Khokra, Sukhbir Lal, Balram Choudhary, and Heena Mehta. "RP-HPLC analysis for the simultaneous estimation of rabeprazole sodium and aceclofenac in a combined dosage form." International Current Pharmaceutical Journal 1, no. 12 (November 1, 2012): 410–13. http://dx.doi.org/10.3329/icpj.v1i12.12450.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

A rapid, simple and highly sensitive reversed phase high performance liquid chromatographic (RP-HPLC) method has been developed for the quantitative determination of Rabeprazole sodium and Aceclofenac in a combined dosage form. Rabeprazole sodium and Aceclofenac were chromatographed using C-18 column as stationary phase and methanol: acetonitrile: water (60 : 10 : 30 v/v/v) as the mobile phase at a flow rate of 1.0 ml/min at ambient temperature and detected at 280 nm. The retention time (RT) of Rabeprazole sodium and Aceclofenac were found to be 5.611 min and 2.102 minute, respectively. The linearities of Rabeprazole sodium and Aceclofenac were in the range of 1-10 µg/ml and 3-15 µg/ml, respectively. The limit of detection was found to be 0.091 µg/ml for Rabeprazole sodium and 0.043 µg/ml for Aceclofenac. The proposed method was applied for the determination of Rabeprazole sodium and Aceclofenac in a combined dosage form and result was found satisfactory.DOI: http://dx.doi.org/10.3329/icpj.v1i12.12450 International Current Pharmaceutical Journal 2012, 1(12): 410-413

25

Polimeni, Giovanni, Paola Cutroneo, Adele Gallo, Salvatore Gallo, Edoardo Spina, and Achille P. Caputi. "Rabeprazole and Psychiatric Symptoms." Annals of Pharmacotherapy 41, no. 7-8 (July 2007): 1315–17. http://dx.doi.org/10.1345/aph.1k134.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Objective: To report the case of a patient who developed marked anxiety associated with episodes of panic attacks after starting rabeprazole therapy. Case Summary: An otherwise healthy 55-year-old woman was prescribed rabeprazole 20 mg/day administered in the morning tor persistent symptoms of dyspepsia. Ten days later, she presented with a 7 day history of marked anxiety associated with panic attacks, night terror (pavor nocturnus), episodic mental confusion, and attention deficit. Within 2 days of discontinuing rabeprazole, the patient recovered completely from the neuropsychiatric manifestations. Subsequent esomeprazole therapy did not cause psychiatric symptoms. Discussion: Rabeprazole-induced hypergastrinemia may have played a role in this neuropsychiatric adverse reaction. Several lines of evidence have indicated that gastrin-releasing peptide, whose release is mediated by proton pump inhibitor (PPI)–induced secretion of gastrin, is involved in regulating aspects of behavior that might be altered in disorders such as anxiety, depression, and dementia. The fact that rabeprazole has the highest capacity of inducing gastrin increase compared with other PPIs might explain why our patient's panic symptoms disappeared after switching to esomeprazole. Based on the Naranjo probability scale, rabeprazole was the probable cause of the adverse reaction. Conclusions: Specific studies are needed to investigate the potential role of PPI-induced hypergastrinemia in neuropsychiatrie adverse reactions.

26

Oridate, Nobuhiko, Ryoji Tokashiki, Yusuke Watanabe, Aki Taguchi, Osamu Kawamura, and Kazuma Fujimoto. "Endoscopic Laryngeal Findings in Japanese Patients with Laryngopharyngeal Reflux Symptoms." International Journal of Otolaryngology 2012 (2012): 1–4. http://dx.doi.org/10.1155/2012/908154.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Objective. To know the characteristics of endoscopic laryngeal and pharyngeal abnormalities in Japanese patients with laryngopharyngeal reflux symptoms (LPRS).Methods. A total of 146 endoscopic images of the larynx and pharynx (60 pairs for the rabeprazole group and 13 pairs for the control group) were presented to 15 otolaryngologists blinded to patient information and were scored according to several variables potentially associated with laryngopharyngeal reflux. The median value of the 15 scores for each item from each image was obtained. The mean pretreatment scores of each item and total score were assessed in both rabeprazole and control groups. In the rabeprazole group, the endoscopic findings before and after the 4-week treatment with rabeprazole were compared. Changes between corresponding duration in the control group were also evaluated.Results. The median and mean pretreatment total score was 3 and 3.02, respectively, from the 73 patients with LPRS. No significant differences were observed before and after treatment in either the rabeprazole or control groups for any item or total score. In 24 patients with a high pretreatment score (total score ≥ 4) from the rabeprazole group, significant decreases in scores for “thick endolaryngeal mucous” (0.54 to 0.17,P=0.017) and total (4.77 to 3.58,P=0.0003) were observed after the 4-week treatment.

27

Trukhan, D. I., E. N. Degovtsov, and A. L. Mazurov. "Choice of protonic pump inhibitor with regard to multimorbidity: a focus on rabeprazol." Medical Council, no. 3 (May 12, 2019): 34–42. http://dx.doi.org/10.21518/2079-701x-2019-3-34-42.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Acid-related diseases occupy a leading place in the structure of the incidence of the gastrointestinal tract. One of the important aspects of studying them now is to consider them in combination with coronary heart disease, hypertension, diabetes, asthma and other common diseases and conditions. Proton pump inhibitors are currently the basis for the treatment of acid-related diseases. Although all PPIs are very effective, the antisecretory effects of various drugs of this class may differ in different patients, especially in the presence of comorbidities and comorbidities. The pharmacokinetics and metabolism of rabeprazole are significantly different from those of other IPPs. The clearance of rabeprazole is largely non-enzymatic and depends little on the functioning of the cytochrome P450 (CYP) 2C19 system, which determines the predictability of the effect of rabeprazole and its safety for patients taking several drugs at the same time. A distinctive effect of rabeprazole is the activation of rabeprazole in a wide pH range, the presence of a gastroprotective effect and anti-helicobacter activity.

28

&NA;. "Lansoprazole/omeprazole/rabeprazole." Reactions Weekly &NA;, no. 1161 (July 2007): 16. http://dx.doi.org/10.2165/00128415-200711610-00051.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

&NA;. "Antirheumatics/bisphosphonates/rabeprazole." Reactions Weekly &NA;, no. 1403 (May 2012): 8. http://dx.doi.org/10.2165/00128415-201214030-00018.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Kekilli, Murat, Alpaslan Tanoglu, Serkan Ocal, and Yavuz Beyazit. "Rabeprazole-Induced Tinnitus." Annals of Pharmacotherapy 48, no. 7 (June 10, 2014): 943. http://dx.doi.org/10.1177/1060028013520596.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Evans, Charity, Gordon Stueck, Sandhya Koobair, Jaimala Maharaj, and Vikesh Maraj. "Patient Acceptance and Economic Outcomes of Rabeprazole Therapy — A Pharmacist-Initiated Interchange Protocol." Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 138, no. 5 (June 2005): 44–49. http://dx.doi.org/10.1177/171516350513800505.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Objective: The purpose of this study was to measure the patient acceptance, as well as the individual and provincial cost savings, of switching from other proton pump inhibitor (PPI) therapies to the less costly rabeprazole. Design and setting: This was an uncontrolled, prospective study conducted at a community pharmacy in conjunction with the physicians at the local medical clinic. Patients: Male and female patients over 18 years of age who were currently taking a PPI (omeprazole, lansoprazole, pantoprazole) regularly and who were under the care of a participating physician were eligible. Patients who were pregnant or breast-feeding were excluded. All patients were switched from their current PPI therapy to rabeprazole 20 mg daily, except for two patients, whose previous dose of omeprazole 20 mg twice daily was changed to rabeprazole 20 mg twice daily. Results: Twenty-six patients were enrolled. All patients were Caucasian; 15/26 (58%) were female, and 11/26 (42%) were male; ages ranged from 43 to 89 years. The PPI therapy being used by patients was omeprazole 20 mg, 77% (20/26); pantoprazole 40 mg, 11.5% (3/26); and lansoprazole 30 mg, 11.5% (3/26). At a six-month follow-up (minimum four months of rabeprazole therapy), seven (26.9%) patients had switched back to their original PPI therapy, while 19 (73.1%) had continued on rabeprazole. Five of the seven (71.4%) patients returned to omeprazole therapy, two (28.6%) returned to lansoprazole, and none (0%) returned to pantoprazole. Annual combined cost savings to individual patients was calculated at $4617.48; cost savings to the provincial government were $5083.56. Conclusion: Based on the literature, on the fact that 73.1% of patients found rabeprazole to be equivalent in efficacy and tolerability to the other more costly PPIs, and on the potential cost savings demonstrated, we believe that rabeprazole should be considered as a first choice for PPI therapy.

32

Dewan, Bhupesh, and Nisha Philipose. "Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial." Gastroenterology Research and Practice 2011 (2011): 1–8. http://dx.doi.org/10.1155/2011/640685.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Background. Empirical therapy with antisecretory agents like PPIs and H2RAs has long been the traditional approach in the initial management of uninvestigated dyspepsia.Aim. The objective of the study was to examine relief of dyspepsia with lafutidine, a second-generationH2-RA, and rabeprazole and to compare their efficacy.Methods. This was a randomized, open, comparative trial in adult uninvestigated dyspeptic patients, who had at least moderate severity of symptoms, defined as a score of≥4 on a 7-point global overall symptom (GOS) scale, and were randomized to receive once daily either lafutidine 10 mg or rabeprazole 20 mg for 4 weeks.Results. A total of 236 patients were enrolled, out of which 194 patients were included in the analysis. At the end of week 4, a significant difference was observed for symptom relief (lafutidine 89.90% versus rabeprazole 65.26%,P<.01) and symptom resolution (lafutidine 70.71% versus rabeprazole 25.26%,P<.01). Both the drugs were well tolerated.Conclusion. Both lafutidine and rabeprazole provide symptom relief in patients with heartburn-dominant uninvestigated dyspepsia. The present study confirms the appropriateness of lafutidine as an empiric treatment and superior efficacy for primary care practice patients with dyspepsia.

33

Bari, Ayesha Abdul, Dr Syed Ibrahim Hassan, Aaminah Najmus Sahar, Syeda Batool Safiyya, and Asif Rasheed. "A PROSPECTIVE STUDY INVOLVING COMPARISON OF ACOTIAMIDE WITH RABEPRAZOLE VS. DOUBLE DOSE RABEPRAZOLE IN PATIENTS HAVING OVERLAPPING SYMPTOMS OF PROTON PUMP INHIBITOR REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE AND FUNCTIONAL DYSPEPSIA." International Journal of Research -GRANTHAALAYAH 8, no. 1 (June 2, 2020): 1–11. http://dx.doi.org/10.29121/granthaalayah.v8.i1.2020.234.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Introduction: Gastroesophageal reflux disease (GERD) is a digestive disorder that affects the lower esophageal sphincter (LES). Functional dyspepsia (FD) is characterized by troublesome early satiety, epigastralgia or heart burn. It is often overlooked as the symptoms overlap with GERD. This study aims to compare the effectiveness of Acotiamide+Rabeprazole vs. a double dose of Rabeprazole in Indian population. Method: In this study 60 patients diagnosed with PPI refractory GERD (taking PPI>8weeks) and FD with no gastric or duodenal organic abnormalities were randomly allocated in two groups. Group 1 received a combination of Acotiamide (200mg/day) +Rabeprazole (20mg/day) and group 2 received a double dose of Rabeprazole (40mg/day). Follow ups were done every month for 3 consecutive months. The frequency and severity of symptoms were assessed using standard Izumo scale and FSSG scale. Results: The total score and GERD score from the baseline were significantly reduced in group 1 however the reduction in FD score from baseline did not differ significantly in the two treatment groups according to F-scale. The proportion of patients with ≥ 50% reduction in the total score for three upper gastrointestinal symptoms (heart burn, epigastralgia, and epigastric fullness) in the izumo scale was 96.7% in group 1 and 33.3% in group 2. Significant difference were noticed between the two groups. No serious adverse events were observed. Conclusion: The combination group of Acotiamide+Rabeprazole was found to be more effective than double dose of Rabeprazole in reducing the overlapping symptoms of PPI refractory GERD and FD.

34

Xia, X. M., and H. Wang. "Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis." Gastroenterology Research and Practice 2013 (2013): 1–6. http://dx.doi.org/10.1155/2013/327571.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Background. Randomized controlled trials (RCTs) have been conducted comparing the efficacy of rabeprazole 20 mg or omeprazole 20 mg once daily for patients with erosive gastroesophageal reflux disease (GERD). Until now, no study has synthesized all available data examining this issue.Method. Medline, Embase, and the Cochrane central register of controlled trials were searched (through December 2012). Eligible RCTs recruited adults with erosive GERD and reported endoscopic and symptomatic relief rates at the last point of follow-up. The effect of rabeprazole versus omeprazole was reported as relative risk (RR) of relief with a 95% confidence interval (CI).Results. The search identified 605 citations, and six RCTs containing 1,895 patients were eligible. Endoscopic relief rates were not significantly different between rabeprazole 20 mg and omeprazole 20 mg in treatment trials of up to 8 weeks. Heartburn relief rates were significantly different between the two groups for 8-week treatment trials. Adverse events were not significantly different between the two groups for 8-week treatment trials.Conclusion. These data suggest that rabeprazole demonstrates a clinical advantage over omeprazole in symptomatic relief but no significant difference in endoscopic relief of erosive GERD for up to 8 weeks of treatment. Rabeprazole and omeprazole were both tolerated by GERD patients.

35

Karra, Uma Mahesh, and Sanjeeva Yarkala. "A Simple and Validated Reverse Phase HPLC Methodfor the Determination of Rabeprazole inPharmaceutical Dosage Forms." E-Journal of Chemistry 7, no. 2 (2010): 569–77. http://dx.doi.org/10.1155/2010/412194.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

A simple and rapid reverse phase high performance liquid chromatography (RP-HPLC) method was developed and validated for quantitative determination of rabeprazole in bulk drug samples and formulations. Rabeprazole was analyzed by using reverse phase LC-GC column (Inertsil ODS, 4.6 mm x 25 cm, 5 microns), with mobile phase consisting of methanol: water (78:22 v/v). The flow rate was set 1.0 mL/min and analysis was performed at wavelength 288 nm using Photo Diode Array (PDA) detector at ambient temperature. The method was validated and stability studies were conducted under different conditions. The retention time for rabeprazole was around 4.12 minutes. The calibration curves were linear (r≥0.9998) over a concentration range from 20.0 to 80.0 μg/mL. Limit of detection (LOD) and Limit of quantitation (LOQ) were 8 ng/mL and 24 ng/mL respectively. The developed method was successfully applied to estimate the amount of rabeprazole in tablet formulations.

36

Miura, Masatomo, Shigeru Satoh, Hitoshi Tada, Tomonori Habuchi, and Toshio Suzuki. "Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes." European Journal of Clinical Pharmacology 62, no. 2 (December 31, 2005): 113–17. http://dx.doi.org/10.1007/s00228-005-0077-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Bakulina, N. V., I. V. Maev, I. V. Savilova, I. G. Bakulin, T. A. Il'chishina, K. A. Zagorodnikova, A. A. Murzina та D. N. Andreev. "Efficacy of H. pylori eradication depending on genetic polymorphism of CYP2C19, MDR1 and IL-1β". Terapevticheskii arkhiv 91, № 8 (15 серпня 2019): 34–40. http://dx.doi.org/10.26442/00403660.2019.08.000380.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Aim. To evaluate an association of genetic polymorphisms CYP2C19, MDR1, and IL-1β on the eradication rate by 10-day modified therapy in patients with H. pylori - associated diseases. Materials and methods. In this study was conducted a prospective, randomized trial, included 89 patients with H. pylori - associated diseases. They were divided into 2 groups depending on therapy: clarithromycin 500 mg, b.i.d., amoxicillin 1000 mg, b.i.d., bismuth subcitrate 240 mg, b.i.d. rabeprazole 20 mg or 40 mg, b.i.d. for 10 days. All subjects underwent pharmacogenetic testing of CYP2C19, MDR1, and IL-1β. Results and discussion. Per - protocol (PP) eradication rates in group with rabeprazole 40 mg were 97.6% (41/42; 95% CI 87.7-99.6), in group with rabeprazole 20 mg were 82.1% (32/39; 95% CI 67.3-91.0). Intention - to - treat analysis in group with rabeprazole 40 mg eradication rates were 89.1% (41/46; 95% CI 77.0-95.3), in group with standard dose rabeprazole - 74.4% (32/43; 95% CI 59.8-85.1). No significant differences in eradication rates between the groups of ultrarapid, rapid, normal and intermediate CYP2C19 metabolizers (PP: 93.5%/90.3%/84.6% respectively; χ2=0.87, p=0.65). Eradication rates in group with IL-1β CC genotype there was no difference among the IL-1β CT and TT genotype groups (PP: 92.9%/85.7%/94.7% respectively; χ2=1.34; p=0.51). The cure rate among MDR1 TT genotype was significantly lower than among subjects in the MDR1 CC/CT genotype groups (PP: 76.2% vs 96.3%: χ2=5.04; p=0.025; OR=8.13). Conclusion. Ten - day modified triple therapy with high dose rabeprazole significantly high eradication rates in patients with H. pylori - associated diseases. Independent factor for treatment failure is MDR1 CC/CT genotype status.

38

Roberto, Michela, Adriana Romiti, Federica Mazzuca, Annalisa Milano, Chiara D’Antonio, Luana Lionetto, Rosa Falcone, et al. "Combination Therapy of High-Dose Rabeprazole Plus Metronomic Capecitabine in Advanced Gastro-Intestinal Cancer: A Randomized Phase II Trial." Cancers 12, no. 11 (October 22, 2020): 3084. http://dx.doi.org/10.3390/cancers12113084.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Background: In recent years, proton pump inhibitors (PPIs) have been investigated at high-dose to modulate tumor microenvironment acidification thus restoring chemotherapeutic sensitivity. This is the first trial to study activity and safety of repurposing high dose rabeprazole combined with metronomic capecitabine (mCAP). Methods: A phase II study in which patients with gastrointestinal cancer, refractory to standard treatments, who had a life expectancy >3 months, were blind randomized 1:1 to mCAP, 1500 mg/daily, continuously with or without rabeprazole 1.5 mg/kg bid, three days a week. The primary endpoint was 3-months progression-free survival (PFS). The secondary endpoints were clinical benefit (CB) and overall survival (OS). Safety and plasma concentrations of capecitabine and its metabolites (5′-DFUR and 5-FU) were also evaluated. Results: Sixty-seven (median age 69 years; 63% male; 84% colorectal cancer, 76% ECOG-PS ≤ 1; 84% pretreated with two or more lines of chemotherapy) out of 90 patients screened for eligibility, were randomized to receive mCAP+rabeprazole (n = 32) vs. mCAP (n = 35). All patients were evaluable for response. No significant difference between mCAP+rabeprazole vs. mCAP, in terms of 3-months PFS rate (HR = 1.43, 95%CI 0.53–3.85; p = 0.477), median PFS (HR = 1.22, 95%CI 0.75–2.00, p = 0.420), CB (RR = 0.85, 95%CI 0.29–2.44; p = 0.786) and median OS (HR = 0.89, 95%CI 0.54–1.48; p = 0.664) was observed. However, a 3-year OS rate of 10% and 12% was reported in the mCAP-rabeprazole and mCAP groups, respectively. Overall, no grade 3 or 4 toxicity occurred but grade 1 or 2 adverse event of any type were more frequently in the mCAP+rabeprazole group than in the mCAP (OR 2.83, 95%CI 1.03–7.79; p = 0.043). Finally, there was not statistically significant difference in the plasma concentration of capecitabine and its metabolites between the two groups. Conclusions: Although the adjunct of high dose rabeprazole to mCAP was not shown to affect mCAP activity, as PPI are being investigated worldwide as drugs to be repositioned in cancer treatment and also considering the limited sample size as well as the favorable safety profile of the combination in the present study, further clinical investigations are desirable.

39

Georges Eter, Elias, Nayla E. Matar, and Amine C. Haddad. "S117 – Gastropharyngeal Reflux and Eustachian Tube Dysfunction." Otolaryngology–Head and Neck Surgery 139, no. 2_suppl (August 2008): P116. http://dx.doi.org/10.1016/j.otohns.2008.05.290.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Objectives Determine the response of gastropharyngeal reflux (GPR) in the pathogenesis of Eustachian tube dysfunction (ETD) in adults, using a therapeutic trial. Methods 18 adult outpatients with symptoms of ETD (associated or not to GPR symptoms) were randomized into two groups: The first group received nasal corticosteroids and Rabeprazole 20mg once daily for 6 weeks. The second group received nasal corticosteroids and placebo for 6 weeks. Symptoms’ severity was evaluated before and after treatment by a tympanometry and a self-administered questionnaire of 7 items focusing on the severity of ETD. Each of the items was scored on a numeric scale. The local ethics committee approval was obtained and patients signed an informed consent before their participation in the study that was conducted between November 2002 and May 2003. Results 8 patients were on Rabeprazole, 10 were on placebo. Patients in the 2 groups were comparable for all the variables except for the severity of symptoms. On enrollment, patients under Rabeprazole had more severe symptoms than those under placebo (SR = 12.4, SP = 7.15 with p = 0.035). At the end of the trial, the improvement of the symptom score under Rabeprazole was significantly higher than that of patients under placebo, using the Mann Whitney test (SR’ = 6.13, SP’ = 11.56 with p = 0.026). Conclusions By showing a significant improvement of ETD symptoms in patients under Rabeprazole compared to controls, this study suggests the response of GPR in the pathogenesis of ETD, but larger studies are needed.

40

Mehetre, Gautam D., Rameshwar S. Cheke, and Vinayak N. Shrikhande. "Formulation and In-Vitro Evaluation of Enteric Coated Tablet Incorporating Rabeprazole." Journal of Drug Delivery and Therapeutics 10, no. 2-s (April 15, 2020): 50–57. http://dx.doi.org/10.22270/jddt.v10i2-s.3953.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The objective of the work is to try and assess the applicability and manufacturing possibilities to optimize an enteric coated tablet formulation containing Rabeprazole sodium as the drug aiming at the anti-acidity activity with desired drug release properties. Enteric coated tablet was chosen as dosage form being a cost-effective technology for pharmaceutical industry requiring fewer procedures. Before the implementation of the pharmaceutical technological aims, analysis of critical factors influencing the manufacture was carried out. Reproducible manufacturing processes are required to achieve suitability and tablets uniformity to achieve the uniform properties of tablets, which could influence experimental parameters. Rabeprazole in core content of tablet is blended with HPMC (different grades), xanthan gum, PVPK30, mannitol, crosspovidone, Sodium starch glycolate, Colloidal silicon dioxide to formulate the product. Prepared formulation was tested for weight and content uniformity, physical characteristics, in vitro dissolution behaviour, acid resistance and accelerated stability studies. All studies performed resulted and revealed for assurance of such enteric coated tablet formulation for drug Rabeprazole with optimum characteristics, concluding it as a promising approach to enhance drug release characteristics. Keywords: Rabeprazole, HPMC, enteric coated tablets, In Vitro evaluation.

41

Kim, Hyung-Keun, Jin-Soo Kim, Tae-Ho Kim, Chang-Whan Kim, Young-Seok Cho, Sung-Soo Kim, Hiun-Suk Chae, et al. "Effect of High-Dose Oral Rabeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcers." Gastroenterology Research and Practice 2012 (2012): 1–8. http://dx.doi.org/10.1155/2012/317125.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Background. The aim of this study was to compare the effect of high-dose oral rabeprazole versus high-dose IV PPI on rebleeding after endoscopic treatment of bleeding peptic ulcers.Methods. This was a two-center, prospective, randomized, controlled trial. Patients with a high-risk bleeding peptic ulcer had endoscopic hemostasis and were randomly assigned to the high-dose oral rabeprazole group (20 mg twice daily for 72 hours) or the high-dose IV omeprazole group (80 mg as a bolus injection followed by continuous infusion at 8 mg/h for 72 hours).Results. The study was stopped because of slow enrollment (totaln=106). The rebleeding rates within 3 days were 3.7% (2 of 54 patients) given oral rabeprazole and 1.9% (1 of 52 patients) given IV omeprazole (P=1.000). The rebleeding rates after 3 days were 1.9% and 0% (P=1.000), respectively. The surgical intervention rates were 3.7% and 0% (P=0.495), and the mortality rates were 1.9% and 0% (P=1.000), respectively.Conclusions. The effect of high-dose oral rabeprazole did not differ significantly from that of high-dose IV omeprazole on rebleeding, surgical intervention, or mortality after endoscopic treatment of bleeding peptic ulcers, but this requires further evaluation.

42

K, Ramya, Munish K S, Ajith K M, and Venkatesha B K. "Effect of Rabeprazole on Pachydermia Laryngis in Patients with Laryngopharyngeal Reflux." Bengal Journal of Otolaryngology and Head Neck Surgery 30, no. 1 (December 3, 2022): 46–50. http://dx.doi.org/10.47210/bjohns.2022.v30i1.609.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Introduction Laryngopharyngeal reflux (LPR) is defined as the retrograde flow of gastric content into larynx and pharynx. It is a multifactorial syndrome. Empiric trial of PPI therapy represents the first step to confirm LPR and to treat it accordingly as all currently available diagnostic tests have poor sensitivity and specificity. However, there is no accepted protocol for the most effective treatment of patients with LPR. Objective of the study was to assess the effect of Rabeprazole on pachydermia laryngis (posterior commissure hypertrophy) in patients with LPR. Materials and Methods In this prospective study, 75 subjects diagnosed with LPR using Reflux symptom index (RSI) and Reflux finding score (RFS) tools were recruited. Using RFS, posterior commissure hypertrophy was scored at presentation and after 8 weeks of rabeprazole therapy. The mean pre- and post-treatment posterior commissure hypertrophy scores for each patient were compared using paired T-test. Results Posterior commissure hypertrophy did not show statistically significant improvement following 8 weeks of 20 mg once daily oral rabeprazole therapy. Conclusion Eight weeks of oral therapy with Rabeprazole 20 mg once daily did not show statistically significant improvement in posterior commissure hypertrophy.

43

Wang, Yi, Guanwu Li, Xiaosu Wang, and Shengliang Zhu. "Effects of Shugan Hewei Granule on Depressive Behavior and Protein Expression Related to Visceral Sensitivity in a Rat Model of Nonerosive Reflux Disease." Evidence-Based Complementary and Alternative Medicine 2019 (January 2, 2019): 1–12. http://dx.doi.org/10.1155/2019/1505693.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Objective. To explore the effect of Shugan Hewei Granule (SGHWG) and to provide the experimental basis for its clinical application.Methods. 40 healthy male Wistar rats were divided into 5 groups, with 8 rats in each group, including control group, model group, normal saline (NS) group, SGHWG group, and Rabeprazole group. The control group was not treated. The model group was treated with fructose intake and mental stress to be the model of NERD. The other groups were treated as the model group and then gavaged with the corresponding drugs. The pH value of lower third of esophagus, immobile time in tail suspension test, CRF protein expression in both hypothalamus and anterior cingulate cortex (ACC), and SP protein in esophageal mucosa in lower third of esophagus detected by immunofluorescence and NMDAR1 protein expression in spinal cord detected by immunohistochemistry of each group were compared.Results. The pH values of both the SGHWG group and the Rabeprazole group were higher than that of the model group (P<0.01), but the Rabeprazole group increased more obviously. The immobile time of the SGHWG group was shorter than that of the model group (P<0.01) and the Rabeprazole group (P<0.05). The expression of the CRF in the hypothalamus and ACC, NMDAR1 in the spinal cord, and SP in the esophageal mucosa in lower third of esophagus of the SGHWG group decreased significantly, compared with the model group (P<0.01), and was obviously lower than that in the Rabeprazole group (P<0.05).Conclusions. This study provided an evidence that SGHW formula was inferior to Rabeprazole in acid inhibition, but it might reduce the expression of CRF protein of hypothalamus and ACC, lower the levels of NMDAR1 in spinal dorsal horn and SP in esophageal mucosa in lower third of esophagus, and regulate depressive behavior simultaneously, related to the improvement of visceral hypersensitivity in rat model of NERD.

44

Alfonzo, Christopher A., William V. Bobo, and Myron D. Almond. "Not a Usual Suspect; Rabeprazole Therapy Presenting as a Severe Neuropsychiatric Illness: Case Report." International Journal of Psychiatry in Medicine 33, no. 3 (September 2003): 311–15. http://dx.doi.org/10.2190/kx4x-ufk5-60kl-wd2g.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

We report the case of a patient who, as a result of exposure to the proton pump inhibitor rabeprazole, developed a severe and disabling admixture of neuropsychiatric symptoms. Because of its widely appreciated placebo-like side effect profile, rabeprazole was never suspected as being the cause of his symptoms. Instead, a somatoform spectrum disorder was assigned based on the patient's atypical symptom presentation, progressive course, subjective psychological distress, intemperate consumption of healthcare resources over a relatively brief period of time and lack of any medical explanation for his symptoms at that time, despite exhaustive laboratory and radiologic work-ups. This case report reinforces the notion that even a medication such as rabeprazole, with an established safety and tolerability profile, may be associated with side effects severe enough to mimic disabling neuropsychiatric illness.

45

"Rabeprazole." Reactions Weekly 1853, no. 1 (May 2021): 415. http://dx.doi.org/10.1007/s40278-021-95281-y.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

"Rabeprazole." Reactions Weekly 1920, no. 1 (August 20, 2022): 414. http://dx.doi.org/10.1007/s40278-022-21951-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

"Rabeprazole." Reactions Weekly 1881, no. 1 (November 2021): 226. http://dx.doi.org/10.1007/s40278-021-05435-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

"Rabeprazole." Reactions Weekly 1876, no. 1 (October 2021): 289. http://dx.doi.org/10.1007/s40278-021-03538-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

"Rabeprazole." Reactions Weekly 1693, no. 1 (March 2018): 434. http://dx.doi.org/10.1007/s40278-018-43324-z.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

"Rabeprazole." Reactions Weekly 1707, no. 1 (June 2018): 237. http://dx.doi.org/10.1007/s40278-018-48053-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.